CN116159062A - 药物组合物及其用途 - Google Patents

药物组合物及其用途 Download PDF

Info

Publication number
CN116159062A
CN116159062A CN202111404293.6A CN202111404293A CN116159062A CN 116159062 A CN116159062 A CN 116159062A CN 202111404293 A CN202111404293 A CN 202111404293A CN 116159062 A CN116159062 A CN 116159062A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
egfr
voumetinib
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111404293.6A
Other languages
English (en)
Chinese (zh)
Inventor
罗会兵
李庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Medicine Polytron Technologies Inc
Original Assignee
Shanghai Allist Medicine Polytron Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Medicine Polytron Technologies Inc filed Critical Shanghai Allist Medicine Polytron Technologies Inc
Priority to CN202111404293.6A priority Critical patent/CN116159062A/zh
Priority to AU2022397653A priority patent/AU2022397653A1/en
Priority to KR1020247020083A priority patent/KR20240124921A/ko
Priority to IL312874A priority patent/IL312874A/en
Priority to CA3238480A priority patent/CA3238480A1/en
Priority to JP2024530487A priority patent/JP2024539476A/ja
Priority to MX2024006168A priority patent/MX2024006168A/es
Priority to US18/712,357 priority patent/US20250017927A1/en
Priority to PCT/CN2022/133171 priority patent/WO2023093663A1/en
Priority to EP22897746.8A priority patent/EP4436580A4/en
Priority to CN202280078292.3A priority patent/CN118678958A/zh
Publication of CN116159062A publication Critical patent/CN116159062A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202111404293.6A 2021-11-24 2021-11-24 药物组合物及其用途 Pending CN116159062A (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN202111404293.6A CN116159062A (zh) 2021-11-24 2021-11-24 药物组合物及其用途
AU2022397653A AU2022397653A1 (en) 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof
KR1020247020083A KR20240124921A (ko) 2021-11-24 2022-11-21 약학적 조성물 및 이의 용도
IL312874A IL312874A (en) 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof
CA3238480A CA3238480A1 (en) 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof
JP2024530487A JP2024539476A (ja) 2021-11-24 2022-11-21 医薬組成物およびその使用
MX2024006168A MX2024006168A (es) 2021-11-24 2022-11-21 Composicion farmaceutica y uso de la misma.
US18/712,357 US20250017927A1 (en) 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof
PCT/CN2022/133171 WO2023093663A1 (en) 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof
EP22897746.8A EP4436580A4 (en) 2021-11-24 2022-11-21 PHARMACEUTICAL COMPOSITION AND ITS USE
CN202280078292.3A CN118678958A (zh) 2021-11-24 2022-11-21 药物组合物及其用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111404293.6A CN116159062A (zh) 2021-11-24 2021-11-24 药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN116159062A true CN116159062A (zh) 2023-05-26

Family

ID=86416859

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111404293.6A Pending CN116159062A (zh) 2021-11-24 2021-11-24 药物组合物及其用途
CN202280078292.3A Pending CN118678958A (zh) 2021-11-24 2022-11-21 药物组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280078292.3A Pending CN118678958A (zh) 2021-11-24 2022-11-21 药物组合物及其用途

Country Status (10)

Country Link
US (1) US20250017927A1 (https=)
EP (1) EP4436580A4 (https=)
JP (1) JP2024539476A (https=)
KR (1) KR20240124921A (https=)
CN (2) CN116159062A (https=)
AU (1) AU2022397653A1 (https=)
CA (1) CA3238480A1 (https=)
IL (1) IL312874A (https=)
MX (1) MX2024006168A (https=)
WO (1) WO2023093663A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116854694A (zh) * 2023-07-04 2023-10-10 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
MX2022007969A (es) * 2019-12-23 2022-12-13 Blueprint Medicines Corp Inhibidores de egfr.
WO2023035223A1 (zh) * 2021-09-10 2023-03-16 上海艾力斯医药科技股份有限公司 药物组合物及其用途
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
WO2024061203A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
CN116854694A (zh) * 2023-07-04 2023-10-10 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用

Also Published As

Publication number Publication date
IL312874A (en) 2024-07-01
JP2024539476A (ja) 2024-10-28
CN118678958A (zh) 2024-09-20
KR20240124921A (ko) 2024-08-19
EP4436580A1 (en) 2024-10-02
MX2024006168A (es) 2024-06-11
CA3238480A1 (en) 2023-06-01
US20250017927A1 (en) 2025-01-16
WO2023093663A1 (en) 2023-06-01
AU2022397653A1 (en) 2024-07-04
EP4436580A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
WO2023035223A1 (zh) 药物组合物及其用途
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
CN113710658A (zh) 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐
AU2020279289B2 (en) Quinoline derivative used for combination treatment of small cell lung cancer
WO2022111714A1 (zh) 用于治疗pik3ca突变癌症的组合疗法
WO2023093663A1 (en) Pharmaceutical composition and use thereof
JP2025163103A (ja) 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
WO2024061203A1 (en) Pharmaceutical composition and use thereof
US12377089B2 (en) Quinoline derivative used for soft tissue sarcoma combination therapy
US20220211694A1 (en) Quinoline derivatives for treatment of head and neck cancer
HK40116696A (zh) 药物组合物及其用途
HK40110967A (zh) 药物组合物及其用途
RU2827402C2 (ru) Фармацевтическая композиция, содержащая пиридинаминное соединение, и ее применение при ros1-положительном немелкоклеточном раке легкого
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物
HK40065487A (en) Quinoline derivative used for soft tissue sarcoma combination therapy
HK40072142A (en) Quinoline derivative used for combination treatment of small cell lung cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230526